Research

Real-world data suggest very low treatment response rates in clinical routine. The search for treatment personalization tools and potential moderators of clinical outcomes is ongoing. Therapeutic Drug Monitoring (TDM), i.e. the quantification of drug concentrations in plasma or serum to titrate the individual dose, is currently the only established personalized medicine tool. Analyzing large TDM datasets acquired as part of clinical practice can help addressing common clinical questions deriving from common clinical scenarios. This type of questions frequently refer to the treatment of particularly vulnerable patient subgroups, where different patterns of drug disposition are expected. For example, the mental healthcare of women in pregnancy or lactation can comprise a challenge for professionals involved including prescription of pharmacological agents. We use different types of data to understand the risk of mental distress in women during pregnancy and at postpartum, while we also focus on exposure of fetuses/newborns to pharmacotherapy prescribed to the mothers during pregnancy and lactation. Moreover, we are interested in understanding moderators of effectiveness and safety outcomes for well-established psychiatric therapies, including electroconvulsive therapy and psychotherapies.

Retrospective analysis of blood levels of psychotropic agents collected in a naturalistic university hospital setting between 2005-2020

Changes in plasma levels of psychotropic medications following SARS-CoV-2 vaccination (2021-2022)

Effects of neuropsychotropic agents on fetal development: a retrospective ultrasonographic study (Master Thesis, Alessia Riediker)

Comparing dosing regimens for antipsychotics: Focus on clozapine (Meta-analysis)

Electroconvulsive Therapy response and safety in patients with comorbid personality disorders (Meta-analysis)

Transfer of anticonvulsants and lithium into amniotic fluid, umbilical cord blood & breast milk: Secondary analysis (Doctorate Thesis: Chiara T. Schmidt)